Nuria Gil

Nuria Gil

Auto-generated profile, based on publicly available information

Nuria Gil

Hospital Gregorio Marañón 2 Department of Pediatric Cardiology Madrid, Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
EBEsther Bernaldo-De-Quirós
Esther Bernaldo-De-Quirós
MCManuela Camino
Manuela Camino
MMMarta Martínez-Bonet
Marta Martínez-Bonet
JGJuan Miguel Gil-Jaurena
Juan Miguel Gil-Jaurena
NGNuria Gil
Nuria Gil
RCRafael Correa-Rocha
Rafael Correa-Rocha
Due to their suppressive capacity, regulatory T cells (Tregs) have attracted growing interest as an adoptive cellular therapy for the prevention of allograft rejection, but limited Treg recovery and lower quality of adult-derived Tregs could represent an obstacle to success. To address this challenge, we developed a new approach that provides large quantities of Tregs with high purity and excellent features, sourced from thymic tissue routinely removed during pediatric cardiac surgeries (thyTregs). We report on a 2-year follow-up of the first patient treated worldwide with thyTregs, included in a phase I/II clinical trial evaluating the administration of autologous thyTreg in infants undergoing heart transplantation. In addition to observing no adverse effects that could be attributed to thyTreg administration, we report that the Treg frequency in the periphery was preserved during the 2-year follow-up period. These initial results are consistent with the trial objective, which is to confirm safety of the autologous thyTreg administration and its capacity to restore the Treg pool.